News and Trends 2 Feb 2023 Almost 20% of cancer trials have recruited only one patient Phesi Inc., a global provider of clinical development data analytics, has published an analysis of site-level enrolment data from 173 cancer clinical trials conducted in the past three years. The data, spanning 83,916 cancer patients from 57 countries, reveals that of the 11,826 investigator sites participating in these trials, 2,298 (19%) enrolled just one patient […] February 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Feb 2023 Recurv Pharma receives funding for cancer therapy development Recurv Pharma Inc. is receiving up to $24 million in funding from TVM Capital Life Science through its TVM Life Science Innovation II SCSp fund. Recurv Pharma plans to develop a novel taxane therapy to treat solid tumors to the proof-of-concept stage. The U.S. based biotech firm is the eighth early-stage or project-focused company (PFC) […] February 2, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Feb 2023 Possible drug targets from Korean atherosclerosis research Research suggests that the enzyme phosphoenolpyruvate carboxykinase 2 (PCK2) and its gene play a role in the development of vascular injury and atherosclerosis. Atherosclerosis is a deadly disease; research suggests that proliferation of vascular smooth muscle cells (VSMCs) and formation of a neointimal layer along the inner lining of arteries play a major role in […] February 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Feb 2023 AstraZeneca creates FRAGLER for DNA synthesis “Plasmids are critical for so many processes in early drug discovery,” says David Öling, associate principal scientist at AstraZeneca. “From protein production, cell line engineering, CAR-T cell therapy, viral vector generation, therapeutic genome editing, mRNA/vaccine production and more. The time it takes and the cost of producing plasmids for DNA constructs is a critical limiting […] February 2, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2023 How can patients have access to the latest science? Innovation in cancer research is happening at an accelerated rate, but the current healthcare system is not equipped to ensure patients can quickly access the latest science. There is a disconnect between treatment innovation and clinical practice. Most cancer patients are seen at community hospitals and treated by generalist oncologists, and data shows that a […] February 1, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2023 Next-generation small molecules hold promise for immunotherapy By Ian B. Walters, chief executive officer and chairman, Portage Biotech In recent years, PD-1/PD-L1 checkpoint antibody therapies have revolutionized the immuno-oncology landscape and offered cancer patients the hope for a long term treatment and cure of their disease. While these treatments have shown great promise in reversing T-cell exhaustion, many patients still have limited […] February 1, 2023 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2023 Advancing cancer care with 3D genomics By Oxford BioDynamics Cancer care is in urgent need of effective tests to determine the best approach for personalized medicine. Practical, new solutions exploiting the power of 3D genomics are emerging. Cancer is a vastly complex, multidimensional disease marked by the uncontrolled proliferation of cells. Many intertwined layers of biological systems give rise to the […] February 1, 2023 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2023 Cancer Genomics: Technological innovation set to fuel research breakthroughs By Neil Ward, vice President and general manager, PacBio EMEA We’ve known for a long time that genomic sequencing can strengthen our understanding of cancer’s highly complex and variable pathology. But to date, embedding genomics into cancer research has been challenging because of limitations in sequencing technology. But with recent innovations, this is changing. Genomic […] February 1, 2023 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2023 The next breakthrough in cancer treatment? In our body, we have an innate immune system and an immune system that is developed throughout life. Part of the innate immune system consists of so-called NK (natural killer) cells. This is a type of immune cell that specializes in killing cancer cells. These cells may be of great importance for cancer treatment in […] January 31, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2023 Active Biotech trial confirms eye treatment safety Active Biotech has announced the completion of the phase I clinical study testing the safety and tolerability of its newly-developed laquinimod eye drop formulation in healthy subjects. According to the results, the eye drop was safe and well tolerated both at single ascending doses and after repeated doses for up to 21 days. No serious […] January 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2023 Stemline Therapeutics’ breast cancer treatment approved The Menarini Group, an Italian pharmaceutical and diagnostics company, says that the U.S. Food and Drug Administration (FDA) has approved ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline Therapeutics, a wholly-owned subsidiary […] January 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2023 Singapore researchers use old drug as new acute leukemia treatment A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore, has revisited an existing drug to combat a type of blood cancer called T-cell acute lymphoblastic leukemia, or T-ALL. The research was led by Takaomi Sanda and Lim Fang Qi. The drug, PIK-75, was initially discovered […] January 31, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email